Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
losartan (losartan potassium)
Alkaloid AD Skopje
C09CA01
losartan (losartan potassium)
50mg
tablets film-coated
(30/3x10/) in blister
Prescription
Registered
2017-12-08
LOTAR 50 mg and 100 mg film-coated tablets Summary of Product Characteristics 1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT LOTAR 50 mg film-coated tablets LOTAR 100 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Lotar 50 mg film-coated tablets Each film-coated tablet contains 50 mg losartan potassium. Each film-coated tablet contains 35,10 mg lactose monohydrate. Lotar 100 mg film-coated tablets Each film-coated tablet contains 100 mg losartan potassium. Each film-coated tablet contains 70,20 mg lactose monohydrate. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM * Film-coated tablets Lotar 50 mg film-coated tablets White, round, biconvex, film-coated tablets with break-mark on one side. Lotar 100 mg film-coated tablets White, round, biconvex, film-coated tablets with a cross-score on one side. 4. CLINICAL PROPERTIES 4.1. THERAPEUTIC INDICATIONS • Treatment of essential hypertension in adults and in children and adolescents 6 - 18 years of age. • Treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus with proteinuria ≥ 0.5 g/day as part of an antihypertensive treatment (see sections 4.3, 4.4, 4.5, and 5.1). • Treatment of chronic heart failure in adult patients when treatment with Angiotensin- converting enzyme (ACE) inhibitors is not considered suitable due to incompatibility_, _ _especially cough, _or contraindication. Patients with heart failure who have been stabilised LOTAR 50 mg and 100 mg film-coated tablets Summary of Product Characteristics 2 with an ACE inhibitor should not be switched to losartan. The patients should have a left ventricular ejection fraction ≤ 40% and should be clinically stable and on an established treatment regimen for chronic heart failure. • Reduction in the risk of stroke in adult hypertensive patients with left ventricular hypertrophy documented by ECG (see section 5.1 LIFE study, Race). 4.2. POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY Hypertens Read the complete document